• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过肽图分析鉴定治疗性单克隆抗体中的降解位点

Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping.

作者信息

Kroon D J, Baldwin-Ferro A, Lalan P

机构信息

R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869.

出版信息

Pharm Res. 1992 Nov;9(11):1386-93. doi: 10.1023/a:1015894409623.

DOI:10.1023/a:1015894409623
PMID:1475223
Abstract

A peptide mapping procedure was developed to locate regions of a monoclonal antibody, OKT3, that undergo chemical modification as the molecule degrades upon storage. The structures of these peptide degradation products were investigated. Deamidation at specific asparagine residues and oxidation of a cysteine and several methionines were found to be major routes of OKT3 degradation. A unique chain cross-linked degradation product was also observed and characterized. Changing the storage conditions of the antibody affected the relative distribution of degradation products. These results were useful in the development of more stable formulations for OKT3, and the methods can be used in the characterization of other monoclonal antibodies intended for therapeutic use.

摘要

开发了一种肽图谱分析方法,以定位单克隆抗体OKT3中在储存过程中分子降解时发生化学修饰的区域。对这些肽降解产物的结构进行了研究。发现特定天冬酰胺残基的脱酰胺作用以及一个半胱氨酸和几个甲硫氨酸的氧化是OKT3降解的主要途径。还观察并表征了一种独特的链交联降解产物。改变抗体的储存条件会影响降解产物的相对分布。这些结果有助于开发更稳定的OKT3制剂,并且该方法可用于表征其他用于治疗的单克隆抗体。

相似文献

1
Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping.通过肽图分析鉴定治疗性单克隆抗体中的降解位点
Pharm Res. 1992 Nov;9(11):1386-93. doi: 10.1023/a:1015894409623.
2
Orthoclone OKT3. Chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody.抗人T细胞单克隆抗体(Orthoclone OKT3)。一种治疗性单克隆抗体降解的化学机制及功能效应
Pharm Biotechnol. 1993;5:135-58.
3
Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies.鉴定和表征单克隆鼠/人嵌合抗体中的氧化和脱酰胺位点。
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):777-84. doi: 10.1016/j.jchromb.2010.01.036. Epub 2010 Jan 29.
4
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.单个氨基酸突变对“人源化”OKT3单克隆抗体激活特性和免疫抑制特性的影响。
J Immunol. 1992 Jun 1;148(11):3461-8.
5
Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping.使用阳离子交换色谱法和肽图谱分析对IgG1的Fc片段中天冬酰胺330脱酰胺作用的表征。
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Aug 15;965:65-71. doi: 10.1016/j.jchromb.2014.06.018. Epub 2014 Jun 21.
6
Identification of deamidation and isomerization sites on pharmaceutical recombinant antibody using H(2)(18)O.利用H₂¹⁸O鉴定药用重组抗体上的脱酰胺化和异构化位点。
Anal Biochem. 2007 Sep 1;368(1):49-60. doi: 10.1016/j.ab.2007.05.012. Epub 2007 May 17.
7
Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3.与治疗性单克隆抗体OKT3复合的人T细胞受体CD3εγ异二聚体的晶体结构
Proc Natl Acad Sci U S A. 2004 May 18;101(20):7675-80. doi: 10.1073/pnas.0402295101. Epub 2004 May 10.
8
Complete and rapid peptide and glycopeptide mapping of mouse monoclonal antibody by LC/MS/MS using ion trap mass spectrometry.
Anal Chem. 1998 Jul 1;70(13):2718-25. doi: 10.1021/ac9712153.
9
Qualification of a Quantitative Method for Monitoring Aspartate Isomerization of a Monoclonal Antibody by Focused Peptide Mapping.通过聚焦肽图分析监测单克隆抗体天冬氨酸异构化定量方法的验证
PDA J Pharm Sci Technol. 2016;70(6):490-507. doi: 10.5731/pdajpst.2015.006239. Epub 2016 Apr 18.
10
Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody.一种抗CD3单克隆抗体的VH和Vκ基因的克隆与测序,以及小鼠/人嵌合抗体的构建。
J Biochem. 1996 Sep;120(3):657-62. doi: 10.1093/oxfordjournals.jbchem.a021462.

引用本文的文献

1
Developability considerations for bispecific and multispecific antibodies.双特异性和多特异性抗体的可开发性考虑因素。
MAbs. 2024 Jan-Dec;16(1):2394229. doi: 10.1080/19420862.2024.2394229. Epub 2024 Aug 27.
2
Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates.蛋白质治疗药物中用于蛋白质稳定化的替代辅料:克服聚山梨酯的局限性
Pharmaceutics. 2022 Nov 23;14(12):2575. doi: 10.3390/pharmaceutics14122575.
3
Micro-Heterogeneity of Antibody Molecules.抗体分子的微观异质性。

本文引用的文献

1
Sensitive quantitative analysis of disulfide bonds in polypeptides and proteins.多肽和蛋白质中二硫键的灵敏定量分析。
Anal Biochem. 1984 Apr;138(1):181-8. doi: 10.1016/0003-2697(84)90786-3.
2
Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation.肽中天冬酰胺基和天冬氨酸残基处的脱酰胺、异构化和消旋化。导致蛋白质降解的琥珀酰亚胺连接反应。
J Biol Chem. 1987 Jan 15;262(2):785-94.
3
In vitro deamidation of human triosephosphate isomerase.人磷酸丙糖异构酶的体外脱酰胺作用
Exp Suppl. 2021;112:1-26. doi: 10.1007/978-3-030-76912-3_1.
4
Monoclonal Antibody Aggregation Associated with Free Radical Induced Oxidation.单克隆抗体聚集与自由基诱导氧化有关。
Int J Mol Sci. 2021 Apr 12;22(8):3952. doi: 10.3390/ijms22083952.
5
Structural and biochemical basis of the formation of isoaspartate in the complementarity-determining region of antibody 64M-5 Fab.抗体 64M-5 Fab 的互补决定区中天冬氨酸异构化形成的结构和生化基础。
Sci Rep. 2019 Dec 6;9(1):18494. doi: 10.1038/s41598-019-54918-0.
6
Structure, heterogeneity and developability assessment of therapeutic antibodies.治疗性抗体的结构、异质性和可开发性评估。
MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17.
7
Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions.在生理条件下评估曲妥珠单抗和内源性人免疫球蛋白的敏感化学修饰位点。
Commun Biol. 2018 Apr 5;1:28. doi: 10.1038/s42003-018-0032-8. eCollection 2018.
8
Analytical comparability study of recombinant monoclonal antibody therapeutics.重组单克隆抗体治疗药物的分析可比性研究。
MAbs. 2018 May/Jun;10(4):513-538. doi: 10.1080/19420862.2018.1438797. Epub 2018 Mar 20.
9
Forced degradation of recombinant monoclonal antibodies: A practical guide.重组单克隆抗体的强制降解:实用指南。
MAbs. 2017 Nov/Dec;9(8):1217-1230. doi: 10.1080/19420862.2017.1368602. Epub 2017 Aug 30.
10
Evaluation of Ion Mobility-Mass Spectrometry for Comparative Analysis of Monoclonal Antibodies.离子淌度-质谱法用于单克隆抗体比较分析的评价。
J Am Soc Mass Spectrom. 2016 May;27(5):822-33. doi: 10.1007/s13361-016-1369-1. Epub 2016 Mar 17.
Arch Biochem Biophys. 1986 Aug 1;248(2):452-9. doi: 10.1016/0003-9861(86)90498-4.
4
Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes.从电转印到聚偏二氟乙烯膜上的皮摩尔量蛋白质中获得的序列。
J Biol Chem. 1987 Jul 25;262(21):10035-8.
5
Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins.细胞蛋白质中天冬氨酸和天冬酰胺残基自发形成琥珀酰亚胺的倾向。
Int J Pept Protein Res. 1987 Dec;30(6):808-21. doi: 10.1111/j.1399-3011.1987.tb03390.x.
6
Formation of isoaspartate at two distinct sites during in vitro aging of human growth hormone.人生长激素体外老化过程中两个不同位点异天冬氨酸的形成。
J Biol Chem. 1989 Aug 25;264(24):14262-71.
7
Stability of protein pharmaceuticals.蛋白质药物的稳定性
Pharm Res. 1989 Nov;6(11):903-18. doi: 10.1023/a:1015929109894.
8
Identification of an isoaspartyl linkage formed upon deamidation of bovine calbindin D9k and structural characterization by 2D 1H NMR.牛钙结合蛋白D9k脱酰胺形成的异天冬酰胺键的鉴定及二维¹H NMR结构表征
Biochemistry. 1989 Oct 17;28(21):8646-53. doi: 10.1021/bi00447a055.
9
Deamidation via cyclic imide in asparaginyl peptides.天冬酰胺肽中通过环状酰亚胺进行的脱酰胺作用。
Pept Res. 1989 Mar-Apr;2(2):195-200.
10
Formation of isoaspartate 99 in bovine and porcine somatotropins.牛和猪生长激素中异天冬氨酸99的形成。
J Protein Chem. 1990 Feb;9(1):109-17. doi: 10.1007/BF01024992.